Heron Therapeutics (HRTX) Total Liabilities (2010 - 2026)

Heron Therapeutics has reported Total Liabilities for 17 years, with the latest figure at $237.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 10.27% year-over-year to $237.1 million; the trailing twelve-month figure through Mar 2026 stood at $237.1 million (down 10.27% YoY), and the FY2025 full-year result was $241.5 million, down 9.47% from the prior year.
• Total Liabilities for Q1 2026 stood at $237.1 million, down from $241.5 million in the prior quarter.
• The five-year high for Total Liabilities was $266.8 million in Q4 2024, with the low at $232.3 million in Q1 2023.
• Historically, Total Liabilities has averaged $250.6 million across 5 years, with a median of $251.7 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 117.74% — and 2026, when it declined 10.27%.
• Heron Therapeutics' Total Liabilities stood at $237.4 million in 2022, then increased by 8.05% to $256.5 million in 2023, then increased by 4.02% to $266.8 million in 2024, then decreased by 9.47% to $241.5 million in 2025, then slipped by 1.85% to $237.1 million in 2026.
• The last three Total Liabilities figures came in at $237.1 million (Q1 2026), $241.5 million (Q4 2025), and $234.1 million (Q3 2025), per Business Quant data.